Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.

@article{Nes2015MinimalIO,
  title={Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.},
  author={Johanna G H van Nes and Louk V. A. M. Beex and Caroline S Seynaeve and Hein Putter and Alexandr {\vS}r{\'a}mek and Susanne Lardenoije and Marjolijn Duijm-de Carpentier and Inge van Rongen and J W R Hans Nortier and Hermien M Zonderland and Cornelis J. H. van de Velde},
  journal={Acta oncologica},
  year={2015},
  volume={54 3},
  pages={349-60}
}
BACKGROUND Mammographic breast density is one of the strongest independent risk factors for developing breast cancer. We examined the effect of exemestane and tamoxifen on breast density in Dutch postmenopausal early breast cancer patients participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. MATERIAL AND METHODS Analogue mammograms of selected TEAM participants before start, and after one and two (and if available after three) years of adjuvant endocrine therapy were… CONTINUE READING